西安蓝晓科技新材料股份有限公司 第五届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西安蓝晓科技新材料股份有限公司（以下简称"公司"或"蓝晓科技"）第 五届监事会第四次会议通知和议案等材料已于 2024 年 12 月 26 日以电子邮件、 书面送达等方式发送至各位监事，并于 2024 年 12 月 30 日在公司会议室召开 会议。本次会议应出席监事 3 人，实际到会 3 人，公司部分高级管理人员参加 了会议。会议由监事会主席李延军先生主持。会议符合《中华人民共和国公司 法》及《公司章程》的有关规定。会议审议通过了如下决议： 一、审议通过《关于调整2021年限制性股票激励计划授予价格的议案》 | 证券代码：300487 | 证券简称：蓝晓科技 | 公告编号：2024-083 | | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转 02 | | 《关于调整 2021 年限制性股票激励计划限制性股票授予价格的公告》详见巨 潮资讯网（http://www.cninfo.com.cn）。 备查文件 第五届 ...

2021 年限制性股票激励计划调整限制性股票 北京德恒律师事务所 关于西安蓝晓科技新材料股份有限公司 授予价格的法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 | 释 义 | 2 | | --- | --- | | 一、本次调整的批准与授权 4 | | | 二、本次调整的具体情况 7 | | | 三、结论性意见 7 | | 北京德恒律师事务所 关于西安蓝晓科技新材料股份有限公司 2021 年限制性股票 激励计划调整限制性股票授予价格的法律意见 释 义 在本法律意见中，除非文义另有所指，下列词语具有下述涵义： | 德恒/本所 | 指 | 北京德恒律师事务所 | | --- | --- | --- | | 公司/蓝晓科技 | 指 | 西安蓝晓科技新材料股份有限公司 | | 《激励计划》/本激励计划 | 指 | 《西安蓝晓科技新材料股份有限公司2021年限 | | /本计划 | | 制性股票激励计划》 | | 《考核管理办法》 | 指 | 《2021 年限制性股票激励计划实施考核管理办 法》 | | 本次调整 | ...

| 证券代码：300487 | 证券简称：蓝晓科技 | 公告编号：2024-082 | | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转 02 | | 西安蓝晓科技新材料股份有限公司 第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西安蓝晓科技新材料股份有限公司（以下简称"公司"或"蓝晓科技"）第五 届董事会第六次会议通知和议案等材料已于 2024 年 12 月 26 日以电子邮件、 书面送达等方式发送至各位董事，并于 2024 年 12 月 30 日在公司会议室召开 会议。本次会议应出席董事 9 人，实际到会 9 人，公司部分监事和相关人员参 加了会议。会议由董事长高月静女士主持。会议符合《中华人民共和国公司法》 （以下简称"《公司法》"）及《公司章程》的有关规定。会议审议通过了如 下决议： 表决情况：6 票赞成，0 票弃权，0 票反对，3 票回避。本议案获表决通过。 备查文件 第五届董事会第六次会议决议 《关于调整 2021 年限制性股票激励计划授予价格的公告》详见巨潮资讯网 （htt ...

西安蓝晓科技新材料股份有限公司（以下简称"公司"）因实施 2024 年前 三季度权益分派，根据公司《创业板向不特定对象公开发行可转换公司债券募集 说明书》及《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》等相关规定，经向深圳证券交易所申请，公司可转换公司债券（债券代码： 123195，债券简称："蓝晓转 02"）自 2024 年 12 月 19 日至本次权益分派股权 登记日（2024 年 12 月 26 日）止暂停转股。具体内容详见公司 2024 年 12 月 18 日在巨潮资讯网披露的《关于"蓝晓转 02"暂停转股的提示性公告》（公告编号： 2024-078）。 根据相关规定，"蓝晓转 02"将于本次权益分派股权登记日后的第一个交 易日（即 2024 年 12 月 27 日）起恢复转股，敬请公司可转换公司债券持有人留 意。 | 证券代码：300487 | 证券简称：蓝晓科技 公告编号：2024-081 | | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转 02 | 西安蓝晓科技新材料股份有限公司 关于"蓝晓转 02"恢复转股的提示性公告 本公司及全体董事会成员 ...

Investment Rating - The report gives a "Buy" rating for the company, Blue Sky Technology [18][20]. Core Viewpoints - Blue Sky Technology is a leading enterprise in the adsorption separation materials industry, with a comprehensive layout across various downstream fields such as water treatment, ultra-purification, biomedicine, hydrometallurgy, food processing, energy conservation, and environmental protection [16][18]. - The company has seen rapid growth, with total revenue increasing from 330 million yuan to 2.49 billion yuan from 2016 to 2023, and net profit rising from 60 million yuan to 720 million yuan during the same period, reflecting compound annual growth rates of 33.3% and 42.0%, respectively [18][52]. Summary by Sections Market Overview - The global market for adsorption separation materials is estimated to be around 50 billion yuan, with the complete technology's output valued at 5-10 times that of the materials [7]. - The ion exchange resin market in China has grown significantly, with production increasing from 172,000 tons in 2009 to 399,000 tons in 2023, representing a compound annual growth rate of 6.1% [7]. Company Operations - Blue Sky Technology has a production capacity of 50,000 tons per year for adsorption separation materials and a designed capacity of 70,000 liters per year for chromatographic fillers [18]. - The company has established high-quality production bases in Gaoling and Pucheng, significantly increasing its production capacity [45]. Financial Performance - In the first three quarters of 2024, the company achieved total revenue of 1.89 billion yuan, a year-on-year increase of 20.0%, and a net profit of 600 million yuan, up 15.1% year-on-year [52]. - The company maintains a research and development expense ratio of around 6%, indicating a strong commitment to innovation [32]. Competitive Landscape - The domestic market for ion exchange resins is characterized by intense competition, with many small players lacking technological strength, while leading companies are moving towards high-level capacity upgrades and innovation [8][32]. - Blue Sky Technology is actively pursuing international expansion to tap into new markets [32]. Future Outlook - The company is expected to continue its growth trajectory, with projected net profits of 840 million yuan, 1.08 billion yuan, and 1.32 billion yuan for 2024, 2025, and 2026, respectively [20].

| 证券代码：300487 | 证券简称：蓝晓科技 | 公告编号：2024-080 | | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转 02 | | 西安蓝晓科技新材料股份有限公司 关于"蓝晓转 02"转股价格调整的公告 本公司及全体董事会成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意西安蓝晓 科技新材料股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监 许可〔2023〕628 号）同意注册，西安蓝晓科技新材料股份有限公司（以下简称 "公司"）向不特定对象发行可转换公司债券（以下简称"可转债"）5,460,645 张， 每张面值为人民币 100 元，发行总额为人民币 54,606.45 万元。公司可转债于 2023 年 5 月 8 日起在深圳证券交易所挂牌交易，债券简称"蓝晓转 02"，债券代码 "123195"。 1 1. 债券代码：123195，债券简称：蓝晓转 02 2. 调整前转股价格：60.43 元/ ...

| 证券代码：300487 | 证券简称：蓝晓科技 | 公告编号：2024-079 | | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转 02 | | 西安蓝晓科技新材料股份有限公司 2024 年前三季度权益分派实施公告 本公司及全体董事会成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者遗漏。 特别提示： 1.西安蓝晓科技新材料股份有限公司（以下简称"公司"）2024 年前三季度权 益分派方案为：以公司现有总股本 507,341,481 股剔除回购专用证券账户中已回 购股份 550,000 股后的股本 506,791,481 股为基数，向全体股东每 10 股派发现金 股利人民币 1.19 元(含税)，不送红股，不以资本公积金转增股本。即公司 2024 年前三季度权益分派的股本基数为 506,791,481 股，实际现金分红总额为人民币 60,308,186.24 元（含税）。 2.因公司回购股份不参与分红，本次权益分派实施后，根据股票市值不变原 则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例 将减小，因此，本次权益分派实施后 ...

| 证券代码：300487 | 证券简称：蓝晓科技 | 公告编号：2024-078 | | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转 02 | | 西安蓝晓科技新材料股份有限公司 2. 转股期限：2023 年 10 月 23 日至 2029 年 4 月 16 日 3. 暂停转股时间：2024 年 12 月 19 日至 2024 年前三季度权益分派股权登记 日 4. 恢复转股时间：2024 年前三季度权益分派股权登记日后的第一个交易日 西安蓝晓科技新材料股份有限公司（以下简称"公司"）将于近日实施 2024 年前三季度权益分派事宜，根据《深圳证券交易所创业板上市公司自律监管指南 第 1 号——业务办理》及《西安蓝晓科技新材料股份有限公司向不特定对象发行 可转换公司债券募集说明书》中"转股价格的调整方式及计算公式"条款的规定 （详见附件），2024 年 12 月 19 日起至本次权益分派股权登记日止，"蓝晓转 02"将暂停转股，本次权益分派股权登记日后的第一个交易日起"蓝晓转 02"将 恢复转股。 在上述期间，公司可转换公司债券正常交易，敬请公司可转换公司债券持 有人留 ...

Investment Rating - The report gives Lanxiao Technology a "Recommend" rating for the first time [4] Core Views - Lanxiao Technology is a leading platform company in the adsorption and separation materials industry, with a comprehensive product portfolio and a diversified downstream application market [3] - The company has significant cost advantages in salt lake lithium extraction and is expanding into other metal extraction fields [3] - The biopharmaceutical market is booming, and the company is a leader in the domestic substitution of chromatography media and solid-phase synthesis carriers [4] - The company's revenue and net profit are expected to grow significantly from 2024 to 2026, with projected revenues of 2.6 billion, 3.219 billion, and 4.013 billion yuan, respectively [4] Adsorption and Separation Materials Industry - Lanxiao Technology is a leader in the adsorption and separation resin industry, with a wide range of applications in wet metallurgy, pharmaceuticals, food processing, environmental protection, and industrial water treatment [15] - The company has a total adsorption material capacity of 50,000 tons and a life science material capacity of 70,000 liters, with flexible expansion potential [16] - The company is the first in the industry to implement a "material + equipment" integrated solution, covering six major application fields [17] Metal Extraction Business - The company is a leader in salt lake lithium extraction technology, with 12 projects completed and a total capacity of 86,000 tons of lithium carbonate/lithium hydroxide [3] - The company has established a South American R&D center in Argentina to provide localized technical services for the "Lithium Triangle" region [3] - The company is also expanding into other metal extraction fields, such as gallium, uranium, cobalt, scandium, and rhenium [3] Life Science Business - The company is a leading domestic supplier of chromatography media and solid-phase synthesis carriers, benefiting from the rapid growth of the biopharmaceutical market [4] - The global biopharmaceutical market is expected to grow from $503 billion in 2023 to $892 billion in 2028, with a CAGR of 9.5%-12.5% [4] - The company has achieved breakthroughs in domestic substitution for CPC extraction resins and 7-ACA enzymatic processes [4] Financial Performance - The company's revenue and net profit have grown rapidly, with revenue increasing from 444 million yuan in 2017 to 2.489 billion yuan in 2023, a CAGR of 33.27% [28] - The company's net profit increased from 93 million yuan in 2017 to 717 million yuan in 2023, a CAGR of 40.51% [28] - The company's gross profit margin has remained stable at 40-50%, while the net profit margin reached a record high of 28.99% in 2023 [33] Future Growth Drivers - The company's future growth is driven by the continuous release of salt lake lithium extraction orders and the rapid growth of the biopharmaceutical sector [4] - The company is expected to maintain high growth in its life science, water treatment, and environmental protection sectors [29] - The company's high-margin business segments are expected to increase their share of total revenue, further enhancing profitability [29]

Investment Rating - The investment rating for the company is "Buy" with a market price of RMB 54.20 and a sector rating of "Outperform" [1]. Core Views - The report highlights that the company has shown steady growth in its performance for the first three quarters of 2024, although there was a quarter-on-quarter decline in Q3 2024. The report remains optimistic about the continuous development of the company's adsorption materials business, maintaining the "Buy" rating [1][4]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of RMB 1.892 billion, representing a year-on-year growth of 19.99%. The net profit attributable to the parent company was RMB 596 million, up 15.10% year-on-year. In Q3 2024, the revenue was RMB 597 million, a year-on-year increase of 4.92%, but a quarter-on-quarter decline of 10.00%. The net profit for Q3 2024 was RMB 192 million, reflecting a year-on-year growth of 11.71% and a quarter-on-quarter decline of 18.13% [4][5]. Business Segment Performance - The revenue from adsorption separation materials accounted for 77.19% of total revenue in the first three quarters of 2024, amounting to RMB 1.460 billion. The system device revenue was RMB 366 million, making up 19.36% of total revenue. The report indicates a continuous increase in the proportion of revenue from adsorption separation materials, showcasing strong customer loyalty and business resilience [4][5]. Profitability Metrics - The gross margin for the first three quarters of 2024 was 48.65%, an increase of 0.20 percentage points year-on-year. The net margin was 31.84%, down 1.21 percentage points year-on-year. The report notes that the Q3 2024 gross margin was 51.20%, up 1.77 percentage points year-on-year and 1.76 percentage points quarter-on-quarter [4][5]. Future Earnings Forecast - The report adjusts the earnings forecast for the company, projecting net profits attributable to the parent company of RMB 836 million, RMB 1.019 billion, and RMB 1.249 billion for 2024, 2025, and 2026 respectively. The corresponding price-to-earnings ratios are expected to be 32.9, 27.0, and 22.0 times [4][7].